Remove Licensing Remove Life Science Remove Marketing Remove Pharma Companies
article thumbnail

4 Life Sciences Trends for 2023

XTalks

The life sciences and healthcare are among the biggest industries globally, and their significance was particularly highlighted during the past couple of years by the COVID-19 pandemic. Given the hyperfocus on the life sciences thanks to COVID, consumers appear to be more autonomous and vocal about their medical demands and choices.

article thumbnail

Money moves: How the biotech market is weathering inflationary storms

Pharmaceutical Technology

After a tumultuous year that weathered the continued impact of a bear market , many in biotech are looking for signs of improvement in 2023. News of layoffs and restructuring have evoked concerns that 2023 could be a year of attrition that will push companies to prioritise key candidates and hold onto their finances.

Marketing 173
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Governments and pharma relationships and implications for antimicrobial resistance

Pharmaceutical Technology

Before the Covid-19 pandemic, government-led investment and engagement in life sciences was relatively restricted worldwide, with the industry mostly funded via private investment. As a result, multiple vaccines, including Pfizer /BioNTech’s mRNA vaccine, Comirnaty, were licensed for use within a year of development beginning.

article thumbnail

Europe: Where is the drug discovery innovation?

Drug Discovery World

Thanks to a prestigious academic legacy, Europe has long been a dominant region for life sciences. Europe is traditionally a life sciences powerhouse, with a strong tradition in pharmaceutical discovery. The oldest, still active pharmaceutical company worldwide, Merck, started life in 1668 in Darmstadt, Germany.

Drugs 59
article thumbnail

Breaking into the global pharmaceutical market

pharmaphorum

In 2022, pharma is truly a global industry, and innovation can come from anywhere. But for small life sciences outside of the USA and Europe, it can still be challenging to break onto this global stage. The company recently raised $16.5 So] we are trying to go for the international market.”. “In

article thumbnail

Veeva Systems Summit, Madrid – pharmaphorum reflects

pharmaphorum

Veeva Systems invited pharmaphorum to attend its industry summit in Madrid this week, a huge event that gathered together over 1,000 individuals from life sciences and pharma. The question is, how can the journey there be accelerated, when on the horizon awaits a life sciences future very much immersed in speciality medicine?

article thumbnail

Improving access to treatments in challenging markets

pharmaphorum

Jirair Ratevosian, executive director of global patient solutions and government affairs at Gilead Sciences, tells us how his company utilised previously developed partnerships and their knowledge of providing global access to HIV treatments to distribute Remdesivir. It’s not a coincidence that we now have over 2.3